In today’s recent session, 0.45 million shares of the RAPT Therapeutics Inc (NASDAQ:RAPT) have been traded, and its beta is 0.14. Most recently the company’s share price was $1.03, and it changed around -$0.08 or -6.83% from the last close, which brings the market valuation of the company to $31.07M. RAPT at last check was trading at a discount to its 52-week high of $27.35, offering almost -2555.34% off that amount. We note from RAPT Therapeutics Inc’s average daily trading volume that its 10-day average is 1.68 million shares, with the 3-month average coming to 480.47K.
RAPT Therapeutics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 3.00. If we narrow it down even further, the data shows that 0 out of 13 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 9 recommended RAPT as a Hold, whereas 2 deemed it a Buy, and 1 rated it as Underweight. RAPT Therapeutics Inc is expected to report earnings per share of -0.43 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
RAPT Therapeutics Inc (NASDAQ:RAPT) trade information
Instantly RAPT has been showing red trend so far today with a performance of -6.83% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.9550 on recent trading dayincreased the stock’s daily price by 47.31%. The company’s shares are currently down -95.86% year-to-date, but still down -41.17% over the last five days. On the other hand, RAPT Therapeutics Inc (NASDAQ:RAPT) is -42.49% down in the 30-day period. We can see from the shorts that 2.67 million shares have been sold at a short interest cover period of 9.95 day(s).
The consensus price target as assigned by Wall Street analysts is $33, which translates to bulls needing to increase their stock price by 96.88% from its current value. Analyst projections state that RAPT is forecast to be at a low of $2 and a high of $55.
RAPT Therapeutics Inc (RAPT) estimates and forecasts
RAPT Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -74.26 percent over the past six months and at a 8.20% annual growth rate that is well below the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 47.21% in revenue this quarter, and will report an increase of 38.82% in the next quarter.
Forecasts for the next quarter put sales growth at �.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -12.39%.
RAPT Dividends
RAPT Therapeutics Inc’s next quarterly earnings report is expected to be released on 2024-Nov-12.
RAPT Therapeutics Inc (NASDAQ:RAPT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.84% of RAPT Therapeutics Inc shares, and 86.65% of them are in the hands of institutional investors. The stock currently has a share float of 88.27%. RAPT Therapeutics Inc stock is held by 144.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 13.5546% of the shares, which is about 5.24 million shares worth $15.97 million.
VANGUARD GROUP INC, with 8.0472% or 3.11 million shares worth $9.48 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
